(Q46804697)

25 December 2017

title

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (English)

1 reference

25 December 2017

0 references

6

E A Stadtmauer

1 reference

25 December 2017

author name string

J F San-Miguel

1

1 reference

25 December 2017

P G Richardson

2

1 reference

25 December 2017

P Sonneveld

3

1 reference

25 December 2017

M W Schuster

4

1 reference

25 December 2017

D Irwin

5

1 reference

25 December 2017

T Facon

7

1 reference

25 December 2017

J-L Harousseau

8

1 reference

25 December 2017

D Ben-Yehuda

9

1 reference

25 December 2017

S Lonial

10

1 reference

25 December 2017

H Goldschmidt

11

1 reference

25 December 2017

D Reece

12

1 reference

25 December 2017

J Bladé

13

1 reference

25 December 2017

M Boccadoro

14

1 reference

25 December 2017

J D Cavenagh

15

1 reference

25 December 2017

R Neuwirth

16

1 reference

25 December 2017

A L Boral

17

1 reference

25 December 2017

D-L Esseltine

18

1 reference

25 December 2017

K C Anderson

19

1 reference

25 December 2017

publication date

17 January 2008

1 reference

25 December 2017

published in

Leukemia

1 reference

25 December 2017

volume

22

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

842-849

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405087

exact match

0 references

cites work

Multiple myeloma in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Renal, hematologic and infectious complications in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Renal Failure in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Renal failure in multiple myeloma. Pathogenesis and prognostic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Renal involvement in multiple myeloma: a 10-year study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405087

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405087

1 reference

25 December 2017

1 reference

25 December 2017